Domov › Nemalicelični pljučni rak › Pennsylvania › Philadelphia

Klinične študije za Nemalicelični pljučni rak v Philadelphia, PA

51 študij za Nemalicelični pljučni rak išče udeležence na lokacijah v Philadelphia in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.

Uradno besedilo študije (angleško)

Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Vključevanje udeležencevFaza 3

Thomas Jefferson University Hospital, Philadelphia
Fox Chase Cancer Center, Philadelphia
Temple University Hospital, Philadelphia
in še 5

Starost 18 in več · Vsi spoli · Posodobljeno 5. okt. 2026 · NCT04267848

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Vključevanje udeležencevFaza 1/2

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

Starost 12 in več · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT04585750

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Vključevanje udeležencevFaza 1

Exelixis Clinical Site #98, Philadelphia

Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT05176483

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

Vključevanje udeležencevFaza 3

Perelman Center for Advanced Medicine ( Site 3205), Philadelphia

Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT07513376

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Vključevanje udeležencevFaza 3

Thomas Jefferson University Hospital, Philadelphia
Jefferson Torresdale Hospital, Philadelphia
Lankenau Medical Center, Wynnewood · 7 mi stran
in še 2

Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT06498635

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Vključevanje udeležencevFaza 3

Alliance Cancer Specialists, PC, Wynnewood · 7 mi stran
Consultants in Medical Oncology and Hematology, P.C., Broomall · 10 mi stran
Alliance Cancer Specialists, PC, Media · 12 mi stran
in še 1

Starost 18 in več · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT07144280

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Vključevanje udeležencevFaza 3

Alliance Cancer Specialists - Media, Media · 12 mi stran

Starost 18–100 · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT05920356

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

Vključevanje udeležencevFaza 3

Research Site, Philadelphia

Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06868277

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

Vključevanje udeležencevFaza 2

University of Pennsylvania, Philadelphia

Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06667908

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Vključevanje udeležencevFaza 2

Thomas Jefferson University Hospital, Philadelphia
Jefferson Health Northeast, Philadelphia

Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06667076

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Vključevanje udeležencevFaza 1

Research Site, Philadelphia

Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06218914

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Vključevanje udeležencevFaza 2

Lankenau Medical Center, Wynnewood · 7 mi stran
Riddle Memorial Hospital, Media · 12 mi stran
Paoli Memorial Hospital, Paoli · 18 mi stran

Starost 18 in več · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT03191149

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Vključevanje udeležencevFaza 3

Thomas Jefferson University, Sidney Kimmel Cancer Center - Clinical Trials Office, Philadelphia
Jefferson Hospital Northeast, Philadelphia

Starost 18 in več · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT06890598

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Vključevanje udeležencevFaza 3

Local Institution - 0504, Philadelphia

Starost 18 in več · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT06561386

Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer

Vključevanje udeležencevOpazovalna študija

Lankenau Medical Center, Paoli · 18 mi stran

Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07028489

An External Control Arm Study in Non-Small Cell Lung Cancer

Vključevanje udeležencevOpazovalna študija

Main Line Health, Wynnewood · 7 mi stran

Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07174388

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Vključevanje udeležencevFaza 2/3

Hospital of the University of Pennsylvania, Philadelphia

Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07100080

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Vključevanje udeležencevFaza 3

Clinical Study Site, Philadelphia

Starost 18 in več · Vsi spoli · Posodobljeno 18. sep. 2026 · NCT06767514

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Vključevanje udeležencevOpazovalna študija

University of Pennsylvania, Philadelphia

Starost 18 in več · Vsi spoli · Posodobljeno 14. sep. 2026 · NCT05059444

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Vključevanje udeležencevFaza 3

Thomas Jefferson University, Sidney Kimmel Cancer Center - Clinical Trials Office, Philadelphia
USO - Alliance Cancer Specialists, PC, Horsham · 16 mi stran

Starost 18 in več · Vsi spoli · Posodobljeno 8. sep. 2026 · NCT06119581

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

Vključevanje udeležencevFaza 3

Thomas Jefferson University - Clinical Research Institute ( Site 0147), Philadelphia

Starost 18 in več · Vsi spoli · Posodobljeno 3. sep. 2026 · NCT06422143

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

Vključevanje udeležencevFaza 1/2

Thomas Jefferson University Research Facility, Philadelphia

Starost 18 in več · Vsi spoli · Posodobljeno 2. sep. 2026 · NCT06043817

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Vključevanje udeležencevFaza 1

Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia

Starost 18 in več · Vsi spoli · Posodobljeno 2. sep. 2026 · NCT07216105

A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

Vključevanje udeležencevFaza 1

Thomas Jefferson University, Philadelphia

Starost 18 in več · Vsi spoli · Posodobljeno 2. sep. 2026 · NCT07027514

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Vključevanje udeležencevFaza 3

Fox Chase Cancer Center, Philadelphia

Starost 18 in več · Vsi spoli · Posodobljeno 1. sep. 2026 · NCT07185997

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

Vključevanje udeležencevOpazovalna študija

Abramson Cancer Center of the University of Pennsylvania ( Site 0010), Philadelphia

Starost 18 in več · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT04165798

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

Vključevanje udeležencevFaza 1/2

Abramson Cancer Center of the University of Pennsylvania ( Site 0010), Philadelphia

Starost 18 in več · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT04165070

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

Vključevanje udeležencevFaza 1

Sidney Kimmel Comprehensive Center at Jefferson, Philadelphia

Starost 18 in več · Vsi spoli · Posodobljeno 21. avg. 2026 · NCT06774963

A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

Vključevanje udeležencevFaza 2

Abramson Cancer Center ( Site 0010), Philadelphia

Starost 18 in več · Vsi spoli · Posodobljeno 18. avg. 2026 · NCT06731907

TCR1188-ABC Cells in KRAS-mutated Cancers

Vključevanje udeležencevFaza 1

University of Pennsylvania, Philadelphia

Starost 18 in več · Vsi spoli · Posodobljeno 6. avg. 2026 · NCT07594067

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

Vključevanje udeležencevFaza 1/2

Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia

Starost 18 in več · Vsi spoli · Posodobljeno 5. avg. 2026 · NCT06706076

AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

Vključevanje udeležencevFaza 1

Thomas Jefferson University, Philadelphia

Starost 18 in več · Vsi spoli · Posodobljeno 30. jul. 2026 · NCT07094113

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Vključevanje udeležencevFaza 1

Jefferson University Hospitals, Philadelphia

Starost 18 in več · Vsi spoli · Posodobljeno 22. jul. 2026 · NCT06179160

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

Vključevanje udeležencevFaza 1/2

Fox Chase Cancer Center, Philadelphia

Starost 18 in več · Vsi spoli · Posodobljeno 21. jul. 2026 · NCT05098132

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

Vključevanje udeležencevFaza 3

Thomas Jefferson University Hospital, Philadelphia

Starost 18 in več · Vsi spoli · Posodobljeno 14. jul. 2026 · NCT06686771

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

Vključevanje udeležencevFaza 3

Abramson Cancer Center, Philadelphia

Starost 18 in več · Vsi spoli · Posodobljeno 25. jun. 2026 · NCT06216301

MOv19-BBz CAR T Cells in FRa+ Cancers

Vključevanje udeležencevFaza 1

University of Pennsylvania, Philadelphia

Starost 18 in več · Vsi spoli · Posodobljeno 18. jun. 2026 · NCT07116057

Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance

Vključevanje udeležencevFaza 2

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

Starost 18 in več · Vsi spoli · Posodobljeno 10. jun. 2026 · NCT04332367

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

Vključevanje udeležencevFaza 1

Perelman Center for Advanced Medicine /ID# 250188, Philadelphia

Starost 18 in več · Vsi spoli · Posodobljeno 4. jun. 2026 · NCT04777994

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Vključevanje udeležencevFaza 2

UPMC Hillman Cancer Center - Part of Frick Hospital, Mount Pleasant · 8 mi stran

Starost 18 in več · Vsi spoli · Posodobljeno 3. jun. 2026 · NCT05642572

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

Vključevanje udeležencevFaza 2

Fox Chase Cancer Center, Philadelphia

Starost 18 in več · Vsi spoli · Posodobljeno 22. maj 2026 · NCT05800587

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Vključevanje udeležencevFaza 2/3

Fox Chase Cancer Center, Philadelphia
Temple University Hospital, Philadelphia
UPMC Hillman Cancer Center - Part of Frick Hospital, Mount Pleasant · 8 mi stran

Starost 18 in več · Vsi spoli · Posodobljeno 5. maj 2026 · NCT06616584